Publication | Open Access

Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States

Antimicrobial SusceptibilityHealth SciencesAntibioticsHealth EconomicsHealthcare-associated InfectionCost EffectivenessOral VancomycinInfection ControlMedicineUnited StatesClostridium Difficile InfectionAntimicrobial ResistanceEpidemiologyDrug Resistance